Visualitza per autoria "Tabernero Cartula, Josep"

Ordena per: Ordre: Resultats:

  • Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study
    Van Cutsem, Eric; Montagut Viladot, Clara; Tabernero Cartula, Josep (American Society of Clinical Oncology, 2019)
    Purpose: To determine the safety and preliminary efficacy of selective combination targeted therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC) in the safety lead-in phase of the open-label, randomized, ...
  • Cancer bioMarkers database
    Tamborero Noguera, David; Rubio Pérez, Carlota; Déu Pons, Jordi; Schroeder, Michael Philipp, 1986-; Vivancos Prellezo, Ana; Rovira Guerín, Ana; Tusquets, Ignasi; Albanell Mestres, Joan; Rodon, Jordi; Tabernero Cartula, Josep; Dienstmann, Rodrigo; González-Pérez, Abel; López Bigas, Núria (Universitat Pompeu Fabra, 2016-10-17)
    The cancer bioMarkers database is curated and maintained by several clinical and scientific experts in the field of precision oncology supported by the European Union’s Horizon 2020 funding. This database is currently being ...
  • Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations
    Tamborero Noguera, David; Rubio Pérez, Carlota, 1990-; Déu Pons, Jordi; Schroeder, Michael Philipp, 1986-; Vivancos Prellezo, Ana; Rovira Guerín, Ana; Tusquets Trias de Bes, Ignacio; Albanell Mestres, Joan; Rodon, Jordi; Tabernero Cartula, Josep; Torres, Carmen de; Dienstmann, Rodrigo; González-Pérez, Abel; López Bigas, Núria (BioMed Central, 2018)
    While tumor genome sequencing has become widely available in clinical and research settings, the interpretation of tumor somatic variants remains an important bottleneck. Here we present the Cancer Genome Interpreter, a ...
  • GDF15 is an eribulin response biomarker also required for survival of DTP breast cancer cells
    Bellio, Chiara; Emperador, Marta; Castellano, Pol; Gris-Oliver, Albert; Canals, Francesc; Sánchez Pla, Alexandre; Zamora, Esther; Arribas, Joaquín; Saura, Cristina; Serra, Violeta; Tabernero Cartula, Josep; Littlefield, Bruce A.; Villanueva, Josep (MDPI, 2022)
    Drug tolerant persister (DTP) cells enter into a reversible slow-cycling state after drug treatment. We performed proteomic characterization of the breast cancer (BC) DTP cell secretome after eribulin treatment. We showed ...
  • Intogen - Catalog of driver mutations
    Tamborero Noguera, David; Rubio Pérez, Carlota; Déu Pons, Jordi; Schroeder, Michael Philipp, 1986-; Vivancos Prellezo, Ana; Rovira Guerín, Ana; Tusquets, Ignasi; Albanell Mestres, Joan; Tabernero Cartula, Josep; Dienstman, Rodrigo; González-Pérez, Abel; López Bigas, Núria (Universitat Pompeu Fabra, 2016-10)
    This database contains the results of the driver analysis performed by the Cancer Genome Interpreter across 6,792 exomes of a pan-cancer cohort of 28 tumor types. Validated oncogenic mutations are identified according to ...
  • LBA-004Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC)
    Argiles, Guillem; Albanell Mestres, Joan; Tabernero Cartula, Josep (Oxford University Press, 2017)
  • OncodriveMUT
    Tamborero Noguera, David; Rubio Pérez, Carlota; Déu Pons, Jordi; Schroeder, Michael Philipp, 1986-; Vivancos Prellezo, Ana; Rovira Guerín, Ana; Tusquets, Ignasi; Albanell Mestres, Joan; Rodon, Jordi; Tabernero Cartula, Josep; Dienstman, Rodrigo; González-Pérez, Abel; López Bigas, Núria (Universitat Pompeu Fabra, 2016-01)
    Bioinformatics method to identify individual driver mutations.
  • Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer
    García-Foncillas, Jesús; Tabernero Cartula, Josep; Élez, Elena; Aranda, Enrique; Benavides, Manuel; Camps, Carlos; Jantus-Lewintre, Eloisa; López, Rafael; Muinelo-Romay, Laura; Montagut Viladot, Clara; Antón, Antonio; López, Guillermo; Díaz-Rubio, Eduardo; Rojo, Federico; Vivancos Prellezo, Ana (Nature Research, 2018)
    BACKGROUND: Liquid biopsy offers a minimally invasive alternative to tissue-based evaluation of mutational status in cancer. The goal of the present study was to evaluate the aggregate performance of OncoBEAM RAS mutation ...
  • TCGI prescription
    Tamborero Noguera, David; Rubio Pérez, Carlota; Déu Pons, Jordi; Schroeder, Michael Philipp, 1986-; Vivancos Prellezo, Ana; Rovira Guerín, Ana; Tusquets, Ignasi; Albanell Mestres, Joan; Rodon, Jordi; Tabernero Cartula, Josep; Dienstman, Rodrigo; González-Pérez, Abel; López Bigas, Núria (Universitat Pompeu Fabra, 2016-10)
    CGI drug prescription assigns targeted drugs to a tumor, based on its genomic alterations, according different levels of evidence (from pre-clinical assays to clinical guidelines).
  • The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.
    Sanchez Martin, Francisco Javier; Bellosillo Paricio, Beatriz; Gelabert-Baldrich, Mariona; Dalmases Massegú, Alba, 1982-; Cañadas Castillo, Israel, 1984-; Vidal Barrull, Joana; Martinez, Alejandro; Argiles, Guillem; Visa Turmo, Laura; Arpí Llucià, Oriol; Iglesias García, Mar; Rovira Guerín, Ana; Albanell Mestres, Joan; Tabernero Cartula, Josep; Montagut Viladot, Clara (American Association for Cancer Research, 2016)
    PURPOSE: Approved anti-EGFR antibodies cetuximab and panitumumab provide significant clinical benefit in patients with metastatic colorectal cancer (MCRC). However, patients ultimately develop disease progression, often ...

Cerca

Visualitza

El meu compte

Amb col·laboració de Complim Participem